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Sayan Sen, MBBS, PHDaABSTRACTISSOBJECTIVES In this study, a systematic analysis was conducted of phasic intracoronary pressure and ﬂow velocity in
patients with severe aortic stenosis (AS) and coronary artery disease, undergoing transcatheter aortic valve replacement
(TAVR), to determine how AS affects: 1) phasic coronary ﬂow; 2) hyperemic coronary ﬂow; and 3) the most common
clinically used indices of coronary stenosis severity, instantaneous wave-free ratio and fractional ﬂow reserve.
BACKGROUND A signiﬁcant proportion of patients with severe aortic stenosis (AS) have concomitant coronary artery
disease. The effect of the valve on coronary pressure, ﬂow, and the established invasive clinical indices of stenosis
severity have not been studied.
METHODS Twenty-eight patients (30 lesions, 50.0% men, mean age 82.1  6.5 years) with severe AS and coronary
artery disease were included. Intracoronary pressure and ﬂow assessments were performed at rest and during hyperemia
immediately before and after TAVR.
RESULTS Flow during the wave-free period of diastole did not change post-TAVR (29.78  14.9 cm/s vs. 30.81  19.6
cm/s; p ¼ 0.64). Whole-cycle hyperemic ﬂow increased signiﬁcantly post-TAVR (33.44  13.4 cm/s pre-TAVR vs. 40.33
17.4 cm/s post-TAVR; p ¼ 0.006); this was secondary to signiﬁcant increases in systolic hyperemic ﬂow post-TAVR
(27.67  12.1 cm/s pre-TAVR vs. 34.15  17.5 cm/s post-TAVR; p ¼ 0.02). Instantaneous wave-free ratio values did not
change post-TAVR (0.88  0.09 pre-TAVR vs. 0.88  0.09 post-TAVR; p ¼ 0.73), whereas fractional ﬂow reserve
decreased signiﬁcantly post-TAVR (0.87  0.08 pre-TAVR vs. 0.85  0.09 post-TAVR; p ¼ 0.001).
CONCLUSIONS Systolic and hyperemic coronary ﬂow increased signiﬁcantly post-TAVR; consequently, hyperemic
indices that include systole underestimated coronary stenosis severity in patients with severe AS. Flow during the
wave-free period of diastole did not change post-TAVR, suggesting that indices calculated during this period are
not vulnerable to the confounding effect of the stenotic aortic valve. (J Am Coll Cardiol Intv 2018;11:2019–31)
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2018.07.019
ABBR EV I A T I ON S
AND ACRONYMS
AS = aortic stenosis
CAD = coronary artery disease
FFR = fractional ﬂow reserve
FFR-ﬂow = whole-cycle
hyperemic ﬂow
iFR = instantaneous wave-free
ratio
iFR-ﬂow = ﬂow during the
wave-free period of diastole
LV = left ventricular
MVR = microvascular
resistance
PdPa-ﬂow = whole-cycle
resting ﬂow
TAVR = transcatheter aortic
valve replacement
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2020A signiﬁcant proportion of patientswith severe aortic stenosis (AS)have concomitant coronary artery
disease (CAD) (1,2). Determining the signiﬁ-
cance of CAD is challenging because tradi-
tional noninvasive and invasive indices of
ischemia have not been validated in this
setting (3). At present the decision to revas-
cularize a coronary lesion in a patient with
severe AS is based on angiography (3). This
anatomic approach is unlikely to correctly
identify those lesions that are truly ﬂow
limiting and may therefore lead to inappro-
priate treatment decisions (4).SEE PAGE 2041Invasive indices of coronary stenosis
severity provide more accurate localizationof ischemia than noninvasive indices (5). There are
several invasive indices of coronary artery stenosis
severity. These are measured either during resting
or hyperemic conditions and can be further divided
into those that use the complete cardiac cycle (Pd/
Pa, fractional ﬂow reserve [FFR] [5]) or only a
period within diastole (instantaneous wave-free ra-
tio [iFR] [6]).
To validate whether an invasive index is accurate
in determining lesion signiﬁcance, in patients with
severe AS, an understanding of how AS affects cor-
onary ﬂow is required. Transcatheter aortic valve
replacement (TAVR) permits unique insights into the
acute effects of AS on coronary physiology (7)
because intracoronary physiology assessment can
be made immediately before and after valve inser-
tion, thereby minimizing any potential confounding
factors. In this study, we aimed to use the TAVR
model to determine how AS affects 1) phasic coro-
nary ﬂow; 2) hyperemic coronary ﬂow; and 3) theaNational Heart and Lung Institute, Hammersmith Hospital, Im
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METHODS
PATIENT POPULATION. Twenty-eight consecutive
patients (30 lesions) with severe AS planned for TAVR
and moderate to severe CAD were included. Recruit-
ing centers were the Hammersmith Hospital, Imperial
College NHS Trust (London, United Kingdom) and
Skane University Hospital (Lund, Sweden). TAVR was
indicated by international guidelines (3), and the
treatment decision was made at a heart team
meeting. Exclusion criteria were known nonviable
myocardium in the area of the corresponding coro-
nary artery being studied, contraindication to the
administration of adenosine, inability to consent, and
weight more than 200 kg. All participants gave writ-
ten informed consent, and the study was given full
ethical approval (14/SC/1103).
CARDIAC CATHETERIZATION PROTOCOL. Cardiac
catheterization and coronary angiography were un-
dertaken via either the transradial or transfemoral
route at the operator’s discretion, using standard
equipment. A guiding catheter was used to intubate
the vessel of interest. Heparin (5,000 U) was admin-
istered intra-arterially. A dual-pressure and Doppler
sensor–equipped 0.014-inch guidewire was used for
all physiological assessments (ComboWire, Volcano,
San Diego, California). The guidewire signal was
normalized in the aorta and then advanced a mini-
mum of 3 vessel diameters distal to the stenosed
segment. After an optimal and stable ﬂow velocity
signal was obtained, resting pressure and ﬂow mea-
surements were recorded. Hyperemia was then
induced using a 150-mg bolus of intracoronary aden-
osine, and hyperemic measurements were made.
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FIGURE 1 Figure Demonstrating an Example of Invasive Pressure and
Doppler Flow Measurements
APV ¼ average peak ﬂow velocity; APV-B ¼ average peak ﬂow velocity at baseline;
APV-P ¼ average peak ﬂow velocity at peak hyperemia. CFR ¼ coronary ﬂow reserve;
FFR ¼ fractional ﬂow reserve; HMR ¼ hyperemic microvascular resistance; HR ¼ heart
rate; HSR ¼ hyperemic stenosis resistance; Pa ¼ aortic pressure; Pd ¼ distal coronary
pressure.
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2021returned to the catheter tip to ensure that there was
no pressure drift. When drift was identiﬁed ($0.01),
all measurements were repeated. Left ventricular
end-diastolic pressure (LVEDP) was recorded using a
pigtail catheter placed in the LV cavity. The entire
protocol was repeated immediately following the
deployment of the new aortic valve. An example of an
invasive pressure and ﬂow trace is shown in Figure 1.
TAVR PROCEDURE. All TAVR procedures were un-
dertaken according to standard clinical protocols. All
patients were treated under local anesthesia. The
valves used were the balloon-expandable Edwards
SAPIEN XT or S3 valve (Edwards Lifesciences, Irvine,
California), the self-expandable Medtronic CoreValve
or Evolut R valve (Medtronic, Minneapolis, Minne-
sota), or the repositionable Lotus valve (Boston Sci-
entiﬁc, Natick, Massachusetts); valve choice was at
the operator’s discretion.
ANALYSIS OF HEMODYNAMIC DATA. The hemody-
namic signals were processed using the associated
instrument console (ComboMap, Volcano) and stored
for ofﬂine analysis. Analog output feeds were taken
from the pressure-velocity console and electrocar-
diograph, fed into a DAQ-Card AI-16E-4 (National
Instruments, Austin, Texas), and acquired at 1 kHz
with LabVIEW (National Instruments). Data were
analyzed ofﬂine using a custom software package
designed with MATLAB (The MathWorks, Natick,
Massachusetts).
Coronary ﬂow velocity (centimeters per second)
was measured at baseline and during hyperemia.
Deﬁnitions of hemodynamic variables were as
follows:FF
iFR
Flo
Wh
Wh
Sys
Hy
Ba
iFR
Sys
Ba
HyR ¼ Pdh/Pah (5)
¼ Pdwfp/Pawfp (6)
w during the wave-free period of diastole
(iFR-ﬂow) ¼ vwfp
ole-cycle hyperemic ﬂow (FFR-ﬂow) ¼ vh
ole-cycle resting ﬂow (PdPa-ﬂow) ¼ vb
tolic ﬂow ¼ vsystole
peremic microvascular resistance (MVR)
¼ Pdh/vh (8)
sal MVR ¼ Pdb/vb (8)
resistance ¼ Pdwfp/vwfp (9)
tolic resistance ¼ Pdsystole/vsystole
sal stenosis resistance ¼ DPb/vb (10)
peremic stenosis resistance ¼ DPh/vh (11)where Pa is mean aortic pressure; Pd is mean
intracoronary pressure distal to a stenosis; wfp is the
wave-free period of diastole; vh is mean ﬂow velocitydistal to a stenosis during hyperemia; vb is mean ﬂow
velocity distal to a stenosis at baseline; DPh is Pa  Pd
during hyperemia; and DPb is Pa  Pd at baseline.
Phasic analysis was performed to identify pressure
and ﬂow characteristics during different periods of
the cardiac cycle. The wave-free period was identiﬁed
using wave-intensity analysis as previously described
(12). A custom-written MATLAB algorithm was used
to separate systole, diastole, and the wave-free
period to facilitate phasic analysis of hemodynamic
data. A schematic outlining how this was performed
is shown in Figure 2.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD unless otherwise stated.
Comparisons before and after TAVR were performed
using a Wilcoxon signed rank test. The threshold for
statistical signiﬁcance was set at 0.05.
RESULTS
PATIENT POPULATION AND PROCEDURAL
CHARACTERISTICS. Twenty-eight patients (30
lesions, 50.0% men, mean age 82.1  6.5 years) were
included. Baseline clinical characteristics are summa-
rized in Table 1. Data regarding quantitative coronary
angiography are shown in Table 2. The baseline echo-
cardiographic and procedural characteristics are sum-
marized in Table 3. Mean peak aortic valve velocity
was 407.18  93.68 cm/s, and mean peak gradient was
70.01 32/85 mmHg with a calculated mean aortic valve
area of 0.68  0.22 cm2 (velocity-time integral method).
FIGURE 2 Outline of the Deﬁnitions and Calculations Used for Hemodynamic Parameters Used in the Phasic Analysis
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2022Pre-TAVR, LV systolic function was normal in 20
patients (71.4%), mildly impaired in 3 patients
(10.7%), moderately impaired in 2 patients (7.1%), and
severely impaired in 3 patients (10.7%). Post-TAVR,
LV systolic function was normal in 20 patients
(71.4%), mildly impaired in 3 patients (10.7%),
moderately impaired in 4 patients (14.3%), and
severely impaired in 1 patient (3.6%). Overall there
was no signiﬁcant difference in ejection fraction or
heart rate post-TAVR, with a strong trend forreduction in LV end-diastolic pressure (p ¼ 0.06)
(Figure 3, Table 3).
Following TAVR, 15 patients (53.6%) had no para-
valvular leak, 13 patients (46.4%) had trivial to mild
paravalvular leak, and no patients had mild to mod-
erate, moderate, or severe paravalvular leak (Table 3).
CORONARY FLOW PRE- AND POST-TAVR. A
summary of coronary hemodynamic parameters pre-
and post-TAVR, under resting conditions and during
hyperemia, is shown in Table 4. An example of
TABLE 1 Baseline Clinical Characteristics
Age (yrs) 82.1  6.5
Male 14 (50.0)
Body mass index (kg/m2) 27.90  4.8
Diabetes 7 (25.0)
Hypertension 16 (57.1)
Hyperlipidemia 19 (67.9)
Former smokers 10 (35.7)
Current smokers 0 (0)
Previous myocardial infarction 1 (3.6)
Previous percutaneous coronary intervention 5 (17.9)
Previous coronary artery bypass grafting 1 (3.6)
Values are mean  SD or n (%).
TABLE 3 Baseline Echocardiographic and Procedural Characteristics
Pre-TAVR Post-TAVR p Value
Peak velocity (cm/s) 407.18  93.68 209.58  46.0 <0.001
Peak gradient (mm Hg) 70.01  32.85 17.58  7.3 <0.001
Mean gradient (mm Hg) 37.64  18.48 8.93  4.2 <0.001
Aortic valve area (cm2) 0.68  0.22 1.48  0.4 <0.001
LV systolic function
Normal 20 (71.4) 20 (71.4) NS
Mildly impaired 3 (10.7) 3 (10.7) NS
Moderately impaired 2 (7.1) 4 (14.3) NS
Severely impaired 3 (10.7) 1 (3.6) NS
LV end-diastolic pressure (mm Hg) 17.63  7.9 15.44  6.6 0.06
Paravalvular leak
None 15 (53.6)
Mild 13 (46.4)
Moderate 0 (0)
Severe 0 (0)
Values are mean  SD or n (%).
LV ¼ left ventricular; TAVR ¼ transcatheter aortic valve replacement.
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2023invasive Doppler ﬂow and pressure traces is shown in
Figure 1. A summary of coronary ﬂow pre- and post-
TAVR is shown in Figure 4.
Whole-cycle hemodynamic parameters. PdPa-ﬂow
increased nonsigniﬁcantly by 18.9  4.4% post-
TAVR (22.13  10.3 cm/s pre-TAVR vs. 24.84  12.5
cm/s post-TAVR; p ¼ 0.10). FFR-ﬂow increased by
25.0  3.8% post-TAVR (33.44  13.4 cm/s pre-TAVR
vs. 40.33  17.4 cm/s post-TAVR; p ¼ 0.004).
Systol ic hemodynamic parameters. Systolic resting
ﬂow increased by 36.8  5.4% post-TAVR (16.48  9.4
cm/s pre-TAVR vs. 21.05  13.1 cm/s post-TAVR;
p ¼ 0.004). Systolic hyperemic ﬂow increased by
31.2  5.4% post-TAVR (27.67  12.1 cm/s pre-TAVR
vs. 34.15  17.5 cm/s post-TAVR; p ¼ 0.01).
Wave-free per iod hemodynamic parameters .
There was no change in resting iFR-ﬂow post-TAVR
(29.78  14.9 cm/s pre-TAVR vs. 30.81  19.6 cm/s
post-TAVR; p ¼ 0.31). Hyperemic iFR-ﬂow was also
unchanged pre- and post-TAVR (44.01  20.6 cm/s
pre-TAVR vs. 42.52  18.4 cm/s post-TAVR; p ¼ 0.87).
COMPARISON OF PdPa-FLOW, iFR-FLOW,
FFR-FLOW. Post-TAVR, PdPa-ﬂow increased by 18.9
 4.4%, FFR-ﬂow increased by 25.0  3.8%, andTABLE 2 Quantitative Coronary Angiographic Data
Target vessel (LAD/LCx/RCA) 16/7/7
Stenosis location (proximal/mid/distal) 12/18/0
Diameter stenosis by QCA (%) 56.11  12.2
Area stenosis by QCA (%) 79.15  10.7
Stenosis length (mm) 18.54  5.4
Minimum luminal diameter (mm) 1.16  0.4
Minimum luminal area (mm2) 1.20  0.9
Values are n or mean  SD.
LAD ¼ left anterior descending coronary artery; LCx ¼ left circumﬂex coronary
artery; QCA ¼ quantitative coronary angiography; RCA ¼ right coronary artery.iFR-ﬂow increased by 5.7  3.2%. PdPa-ﬂow changed
signiﬁcantly more than iFR-ﬂow (p ¼ 0.01). FFR-
ﬂow also changed signiﬁcantly more than iFR-ﬂow
(p < 0.0001) (Figure 4). The change in FFR-ﬂow was
similar to the change in PdPa-ﬂow (p ¼ 0.39).
MVR PRE- AND POST-TAVR. Whole-cycle hemodynamic
parameters.Whole-cycle resting MVR was unchanged
post-TAVR (4.20  1.9 mm Hg $ cm $ s1 pre-TAVR vs.
4.14  2.1 mm Hg $ cm $ s1 post-TAVR; p ¼ 0.81).
Whole-cycle hyperemic MVR decreased by 7.7% post-
TAVR (2.42  0.9 mm Hg $ cm $ s1 pre-TAVR vs. 2.14
 0.9 mm Hg $ cm $ s1 post-TAVR; p ¼ 0.03).
Systol i c hemodynamic parameters . Systolic
resting MVR decreased numerically post-TAVR (7.54
3.8 mm Hg $ cm $ s1 pre-TAVR vs. 6.60  3.5 mm Hg $
cm $ s1 post-TAVR; p ¼ 0.17). Systolic hyperemic MVR
did not change post-TAVR (3.73  1.6 mm Hg $ cm $ s1
pre-TAVR vs. 3.45  1.6 mm Hg $ cm $ s1 post-TAVR;
p ¼ 0.12).
Wave-f ree per iod hemodynamic parameters .
Wave-free resting MVR increased by 28.6% post-
TAVR (2.59  1.5 mm Hg $ cm $ s1 pre-TAVR vs.
3.02  1.6 mm Hg $ cm $ s1 post-TAVR; p ¼ 0.02).
Wave-free hyperemic MVR was constant post-TAVR
(1.53  0.8 mm Hg $ cm $ s1 pre-TAVR vs. 1.49 
0.6 mm Hg $ cm $ s1 post-TAVR; p ¼ 0.52).
INDICES OF CORONARY STENOSIS SEVERITY
BEFORE AND AFTER TAVR. iFR values did not
change post TAVR (0.88  0.09 pre-TAVR vs. 0.88 
0.09 post-TAVR; p ¼ 0.94) (Figure 5). FFR values
signiﬁcantly decreased after TAVR (0.87  0.08 pre-
TAVR vs. 0.85  0.09 post-TAVR; p ¼ 0.0008). Basal
FIGURE 3 Figure Outlining the Changes in Ejection Fraction, Heart Rate, and Left Ventricular End-Diastolic Pressure Before and After
Transcatheter Aortic Valve Replacement
The large diamonds denote the mean values, with the error bars denoting the upper and lower 95% conﬁdence intervals.
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2024stenosis resistance values did not change post-TAVR
(0.31  0.29 pre-TAVR vs. 0.32  0.26 post-TAVR;
p ¼ 0.5). Hyperemic stenosis resistance values
increased after TAVR (0.34  0.32 pre-TAVR vs.
0.40  0.32 post-TAVR; p ¼ 0.06). A summary of the
indices of coronary stenosis severity before and after
TAVR is shown in Table 5.
DISCUSSION
In this study, we have shown that 1) iFR-ﬂow does
not change post-TAVR; 2) FFR-ﬂow increases signif-
icantly post-TAVR; 3) changes in FFR-ﬂow are
driven by signiﬁcant increases in systolic ﬂow
post-TAVR; and 4) iFR values do no change
post-TAVR, whereas FFR decreases signiﬁcantly
post-TAVR.
PHASIC CORONARY FLOW IN PATIENTS WITH
SEVERE AS. Coronary ﬂow is phasic and occurs in
both systole and diastole. Systolic ﬂow is drivenpredominantly by pressure changes at the aortic end
of the vessel (13). Diastolic ﬂow is driven by pressure
changes at the distal end of the vessel, due to
contraction and relaxation of the myocardium and its
interaction with the microcirculation (14–16).
During systole, coronary ﬂow is a function of blood
emptying from the left ventricle through the aortic
valve into the aorta and the opposing compression
forces from the contracting myocardium, which
blunts systolic ﬂow. In severe AS, systolic coronary
ﬂow is reduced because of obstruction of ventricular
emptying by the stenosed aortic valve and simulta-
neous compression of the microcirculation from the
contracting myocardium opposing forward ﬂow in the
coronary artery, which is augmented by the elevated
intraventricular pressure in patients with severe AS
(17,18). This results in a reduction in coronary ﬂow
during systole. Treatment of the valve stenosis by
TAVR removes the mechanical obstruction to ven-
tricular emptying, increases aortic ﬂow, and reduces
intraventricular pressure and therefore increases
TABLE 4 Summary of Coronary Hemodynamic Variables at Rest and During Hyperemia Before and After
Transcatheter Aortic Valve Replacement
Resting Hyperemia
Pre-TAVR Post-TAVR p Value Pre-TAVR Post-TAVR p Value
Whole-cycle variables
Flow velocity (cm/s) 22.13  10.3 24.84  12.5 0.10 33.44  13.4 40.33  17.4 0.004*
Microvascular resistance (mm Hg $ cm $ s1) 4.20  1.9 4.14  2.1 0.81 2.42  0.9 2.14  0.9 0.03*
Aortic pressure (mm Hg) 85.85  18.9 92.40  1859 0.04* 82.99  18.0 88.44  17.1 0.13
Systolic variables
Flow velocity (cm/s) 16.48  9.4 21.05  13.1 0.004* 27.67  12.1 34.15  17.5 0.01*
Microvascular resistance (mm Hg $ cm $ s1) 7.54  3.8 6.60  3.5 0.17 3.73  1.6 3.45  1.5 0.12
Aortic pressure (mm Hg) 101.46  22.4 112.11  24. 0.02* 98.87  22.7 110.55  20.7 0.008*
Wave-free variables
Flow velocity (cm/s) 29.78  14.9 30.81  19.6 0.31 44.01  20.6 42.52  18.4 0.87
Microvascular resistance (mm Hg $ cm $ s1) 2.59  1.5 3.02  1.6 0.02* 1.53  0.8 1.49  0.6 0.52
Aortic pressure (mm Hg) 73.05  15.1 76.41  16.8 0.17 70.13  16.3 70.69  15.0 0.64
Diastolic variables
Flow velocity (cm/s) 31.67  15.4 33.33  18.6 0.36 46.03  20.5 45.94  18.1 0.92
Microvascular resistance (mm Hg $ cm $ s1) 2.65  1.5 2.62  1.3 0.92 1.50  0.8 1.47  0.6 0.63
Aortic pressure (mm Hg) 76.76  16.6 78.13  17.0 0.33 71.69  14.9 74.02  15.3 0.34
Values are mean  SD. *Statistically signiﬁcant (p < 0.05).
TAVR ¼ transcatheter aortic valve replacement.
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2025systolic coronary ﬂow (19). This signiﬁcant systolic
increment in ﬂow post-TAVR occurs at rest and dur-
ing hyperemia (Figure 6).
Diastolic ﬂow during the wave-free period occurs
when the myocardium is neither contracting nor
actively relaxing (12). During this period, the aortic
valve is closed. Restriction of aortic valve opening, a
systolic phenomenon, therefore does not affect ﬂow
during the wave-free period of diastole, because
regardless of the severity of AS, the aortic valve
leaﬂets are closed and therefore the aortic valve is not
actively contributing to coronary ﬂow.
THE EFFECT OF AORTIC STENOSIS ON HYPEREMIC
FLOW. Maximal blood ﬂow in a coronary artery is
affected by microvascular structure, function, LV
end-diastolic pressure, and right atrial pressure
(20–23). Any condition that affects 1 of these de-
terminants will affect maximal ﬂow. In AS, LV after-
load is increased because of the stenosed valve (24).
This results in raised LV end-diastolic pressure
and LV hypertrophy, leading to structural changes
in the microcirculation that affect its ability to
respond to hyperemic agents (25). Furthermore,
patients with severe AS have increased circulating
vasoconstrictors as part of a compensatory mecha-
nism to increase vascular tone and maintain systemic
blood pressure (26). These vasoconstrictors coun-
teract the effect of administered vasodilators such
as adenosine and may therefore also attenuate
the response of the coronary microcirculation to
adenosine.The protocol in this study permitted the isolation
of the acute effect of treating a stenosed aortic valve
on coronary hemodynamics. This study demon-
strates that hyperemic ﬂow increases signiﬁcantly
post-TAVR. This is driven by a signiﬁcant increase in
the systolic component of ﬂow. In contrast, ﬂow
during the wave-free period does not change during
hyperemia post TAVR, which is consistent with the
minimal effect of the aortic valve on coronary ﬂow
during this period. Therefore, any index of coronary
ﬂow that includes the systolic phase of the cardiac
cycle will be susceptible to change post-TAVR. In
contrast, indices of ﬂow that do not involve systole
may be less vulnerable to restriction of aortic valve
opening.
INDICES OF CORONARY STENOSIS SEVERITY AND
AORTIC STENOSIS. A signiﬁcant proportion of pa-
tients with severe AS also have concomitant CAD (2).
The assessment of this disease is challenging, and the
established hyperemia-based indices of coronary
stenosis severity have not been validated in this
setting. Extrapolation of FAME (Fractional Flow
Reserve Versus Angiography for Multivessel Evalua-
tion) (4) data would suggest that treatment based on
coronary angiography alone is likely to lead to un-
necessary revascularization. In addition, coronary
intervention is not without risk in patients with
severe AS.
The 2 most clinically applicable and validated
indices of coronary stenosis severity are FFR and iFR.
Although these are both pressure-derived indices of
FIGURE 5 Changes in Fractional Flow Reserve and
Instantaneous Wave-Free Ratio After Transcatheter
Aortic Valve Replacement
Figure demonstrating the change in fractional ﬂow reserve
(FFR) and instantaneous wave-free ratio (iFR) values after
transcatheter aortic valve replacement. FFR decreases signiﬁ-
cantly, whereas iFR remains constant. The bars denote mean
values, with the error bars denoting SEs.
FIGURE 4 Coronary Flow Velocity Before and After
Transcatheter Aortic Valve Replacement
Figure demonstrating the changes in coronary ﬂow before and
after transcatheter aortic valve replacement (TAVR). The left
side of the graph is resting ﬂow over the whole cardiac cycle
(PdPa-ﬂow); themiddle side of the graph is resting ﬂow during
the wave-period of diastole (iFR-ﬂow); and the right side of
the graph is hyperemic ﬂow over the whole cardiac cycle
(FFR-ﬂow). Both PdPa-ﬂow and FFR-ﬂow increase signiﬁcantly
more post-TAVR than iFR-ﬂow, which is constant. The bars
denote mean values, with the error bars denoting SEs.
TABLE 5 Indices of Coronary Stenosis Severity Before and After
Transcatheter Aortic Valve Replacement
Pre-TAVR Post-TAVR p Value
Hyperemic indices
Fractional ﬂow reserve 0.87  0.08 0.85  0.09 0.0008
Hyperemic stenosis resistance 0.34  0.32 0.40  0.32 0.06
Resting indices
Instantaneous wave-free ratio 0.88  0.09 0.88  0.09 0.94
Basal stenosis resistance 0.31  0.29 0.32  0.26 0.50
Pd/Pa 0.91  0.29 0.92  0.06 0.82
Diastolic Pd/Pa 0.88  0.10 0.89  0.09 0.75
Values are mean  SD.
TAVR ¼ transcatheter aortic valve replacement.
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2026stenosis severity, their physiological principles rely
on the fact that pressure is proportional to underlying
coronary ﬂow during their measurement. Therefore,
any change in coronary ﬂow will lead to a change in
the pressure-only index.
FFR is measured over the whole cardiac cycle. As
a result, it includes systolic ﬂow. The signiﬁcant
change in hyperemic systolic ﬂow immediately after
TAVR has a signiﬁcant effect on whole-cycle ﬂow
and therefore FFR. The blunted whole-cycle hyper-
emic ﬂow pre-TAVR leads to FFR’s systematically
underestimating coronary stenosis severity in the
presence of AS, with an increase in hyperemic ﬂow
post-TAVR resulting in FFR values becoming
signiﬁcantly lower across the same coronary steno-
sis (Figure 7).
iFR is a nonhyperemic index of stenosis severity
that is measured during the diastolic wave-free
period (6). During this period pressure and ﬂow are
proportional. We demonstrate that this diastolic
wave-free period exists in patients with severe AS.
Furthermore, coronary ﬂow during the diastolicwave-free period does not change post-TAVR, indi-
cating its relative independence from the acute relief
of AS. This ability to discriminate the coronary ste-
nosis severity from AS appears to be true of this
period at rest and during hyperemia. The consistency
of ﬂow during this period post-TAVR means that, in
FIGURE 6 Changes in Systolic Coronary Flow After Transcatheter Aortic Valve Replacement
Figure demonstrating the changes in systolic coronary ﬂow after transcatheter aortic valve replacement (TAVR). (A) There is a schematic, demonstrating that post-
TAVR there is increase in the forward traveling systolic pressure, leading to an increase in systolic coronary ﬂow. There is also a reduction in the compressive forces on
the microcirculation post-TAVR; these 2 factors both contribute to a net increase in systolic coronary ﬂow post-TAVR. (B) Statistically signiﬁcantly increase in systolic
coronary ﬂow seen in our study, both at rest and during Hyperemia. The bars denote mean values, with the error bars denoting SEs.
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2027contrast to FFR, the iFR value does not change post-
TAVR (Figure 7).
These phenomena can also be observed by
comparing the results of our study with those
of other studies on indices of coronary stenosis
severity in patients without severe AS. In the
DEFINE-FLAIR (Functional Lesion Assessment of
Intermediate Stenosis to Guide Revascularisation)and iFR-SWEDEHEART (Evaluation of iFR vs FFR
in Stable Angina or Acute Coronary Syndrome) trials,
the mean iFR values were 0.91  0.09 and 0.91  0.10,
respectively, similar to the mean iFR of 0.88  0.09
seen in this study. The mean FFR values, however,
were 0.83  0.09 in DEFINE-FLAIR and 0.82  0.10 in
iFR-SWEDEHEART, lower than those seen in this
study (0.87  0.08). This is a function of the
FIGURE 7 Coronary Hemodynamic Status Before and After Transcatheter Aortic Valve Replacement, Over Both the Fractional Flow
Reserve and Instantaneous Wave-Free Ratio Measurement Windows
Figure demonstrating the changes in coronary hemodynamic status over the fractional ﬂow reserve (FFR) and instantaneous wave-free ratio
(iFR) measurement windows. The top row shows the changes in coronary hemodynamics over the FFR window (the whole cardiac cycle
during hyperemia): the left panel demonstrates a signiﬁcant increase in ﬂow, the middle panel demonstrates a signiﬁcant reduction in
resistance; and as a consequence the right panel demonstrates a signiﬁcant reduction in the FFR value after transcatheter aortic valve
replacement (TAVR). The bottom row shows the changes in coronary hemodynamic status over the iFR window (the wave-free period of
diastole at rest): the left panel demonstrates constant ﬂow before and after TAVR; the right panel demonstrates a constant iFR value
post-TAVR; to achieve the same pressure gradient with the same ﬂow velocity, there is therefore a signiﬁcant increase in resistance (shown in
the middle panel). The bars denote mean values, with the error bars denoting SEs.
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2028attenuated hyperemia in these patients, due to a
blunted effect of adenosine resulting in failure to
augment ﬂow sufﬁciently to produce FFR values
similar to those in patients without severe AS.There is a paucity of available data regarding
coronary stenosis assessment in patients with se-
vere AS. Existing studies have not measured cor-
onary ﬂow and assumed that it is not affected by
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2029AS (27–29). The present study demonstrates that
the effect of adenosine is signiﬁcantly altered in
the presence of AS, and this will consequently
signiﬁcantly affect FFR values and therefore any
FFR treatment threshold. The signiﬁcantly blunted
effect of adenosine in these patients suggests that
the fundamental intracoronary conditions for ac-
curate FFR assessment cannot be met in patients
with severe AS and therefore calls into question
the role of FFR as an ischemic standard in these
patients (30).
CLINICAL IMPLICATIONS. The ﬁndings of this study
have potential implications for patients with severe
AS and coronary disease who are undergoing TAVR.
The ability to isolate coronary stenosis severity in
the context of AS will allow clinicians to determine
in which patients the valve alone can be treated
and which patients need concomitant revasculari-
zation, which may be via angioplasty or, in con-
ventional surgical aortic valve replacement, bypass
surgery. Hyperemic indices that include systole,
such as FFR, are unable to accurately determine
coronary stenosis severity in this setting, because of
a blunted hyperemic response, suggesting that
potentially ﬂow-limiting coronary lesions may be
denied appropriate treatment. The degree of AS at
which hyperemic ﬂow begins to reduce is also un-
known, raising the possibility maximal hyperemia is
not achievable in patients with moderate or even
mild AS. Furthermore, the variable and unpredict-
able rate of regression of LV hypertrophy also sug-
gests that FFR may still be vulnerable to an inability
to achieve maximal hyperemia for several months
after valve treatment.
Flow during the wave-free period of diastole is
independent of the severity of the AS, suggesting that
iFR can be used to accurately discriminate coronary
stenosis severity in the setting of AS. Further studies
are required to determine if there is any signiﬁcant
effect of LV hypertrophy regression on iFR values in
this setting. The true of role of iFR in patients will be
appreciated only with a prospective study comparing
an iFR-guided approach to revascularization to stan-
dard angiographically guided therapy in patients with
severe AS.
STUDY LIMITATIONS. This study included patients
with severe symptomatic AS for whom TAVR was
decreed the most appropriate therapy by the heart
team, in accordance with international guidelines (3).
Our results cannot therefore be generalized to pa-
tients with more mild degrees of AS.Adenosine was administered as an intracoronary
bolus and not via intravenous infusion. We cannot
therefore exclude the possibility that intravenous
adenosine infusion would yield different results.
However, intracoronary adenosine is recognized as
a valid approach to FFR assessment (31,32), and
such assessments have been included in all the large
randomized trials of physiology to date (33,34).
Intravenous infusion was avoided because of the
recognized potential for a 15% reduction in aortic
pressure (35) that could potentially destabilize a
patient with severe AS.
Post-TAVR physiological measurements were
made immediately after the valve had been replaced
and within the same catheter laboratory procedure.
We cannot therefore comment on any more long-term
changes in coronary hemodynamics.
The prevalence of severe aortic regurgitation has
been signiﬁcantly reduced with the development of
the current generation of TAVR valves (36). This is
reﬂected in the presence of only trivial to mild aortic
regurgitation in our dataset compared with other
groups that used earlier generation valves (37,38). It
is therefore unlikely that the degree of AR, which was
mild at most in a minority of our patients, would
explain the large differences seen in this study be-
tween systolic and diastolic parameters and hyper-
emia and resting parameters.
The sample size of our study may be considered
small, with 30 coronary lesions across 28 patients.
However, this is the largest study to date of inva-
sive coronary ﬂow in patients with severe AS and
the ﬁrst to study patients with stenosed coronary
arteries. It is also the ﬁrst study to include phasic
analysis, permitting an increase in our understand-
ing of the coronary physiology in this complex he-
modynamic condition. This was a mechanistic
study, aiming to provide a comprehensive insight to
coronary hemodynamic status in patients with se-
vere AS undergoing TAVR. A decision-making
strategy for revascularization in patients with se-
vere AS, on the basis of current FFR or iFR data,
cannot be made.
This study was designed to compare hyperemic
and resting coronary ﬂow and to perform a phasic
analysis to delineate differences between systole
and diastole. It was not, however, powered to
detect differences between resting indices of cor-
onary stenosis severity. Our phasic analysis sug-
gests that there is a signiﬁcant change in systolic
ﬂow post-TAVR, during both resting conditions
and hyperemia. This suggests that if the sample
PERSPECTIVES
WHAT IS KNOWN? A signiﬁcant proportion of
patients with severe AS have concomitant CAD. There
is no established index of coronary stenosis severity in
these patients.
WHAT IS NEW? Systolic coronary ﬂow and
hyperemic coronary ﬂow are signiﬁcantly reduced in
severe AS and change signiﬁcantly post-TAVR, making
indices of coronary stenosis severity that include
systole and are made during hyperemic conditions
unreliable in this context. Coronary ﬂow during the
wave-free period of diastole does not change post-
TAVR, therefore indices restricted to this period are
more accurate in patients with severe AS.
WHAT IS NEXT? Prospective randomized trials of
coronary revascularization in patients with severe AS
are required to determine the optimal method of
assessing and treating CAD in this cohort.
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2030size were increased, we may see signiﬁcant dif-
ferences between whole cycle and diastolic resting
indices.
CONCLUSIONS
Systolic coronary ﬂow and hyperemic coronary ﬂow
are signiﬁcantly reduced in severe AS and change
signiﬁcantly post-TAVR. Hyperemic indices that
include systole therefore provide a limited assess-
ment of true coronary stenosis severity in patients
with severe AS. Flow during the wave-free period of
diastole does not change post TAVR, suggesting that,
in patients with severe AS, coronary indices calcu-
lated during this period may be more reﬂective of true
coronary stenosis severity.
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